Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases Be Safely Resolved by Vitamin D Supplementation

Overview

Journal N Am J Med Sci

Specialty General Medicine

Date 2015 Apr 4

PMID 25838999

Citations 34

Authors

Maksim Khayznikov

Kallish Hemachrandra

Ramesh Pandit

Ashwin Kumar

Ping Wang

Charles J Glueck

Affiliations

Soon will be listed here.

Abstract

Background: Low serum vitamin D can cause myalgia, myositis, myopathy, and myonecrosis. Statin-induced myalgia is a major and common cause of statin intolerance. Low serum vitamin D and statins, additively or synergistically, cause myalgia, myositis, myopathy, and/or myonecrosis. Statin-induced myalgia in vitamin D deficient patients can often be resolved by vitamin D supplementation, normalizing serum vitamin D levels.

Aims: In 74 men and 72 women (age 59 ± 14 years) intolerant to ≥2 statins because of myalgia, myositis, myopathy, or myonecrosis and found to have low (<32 ng/mL) serum vitamin D, we prospectively assessed whether vitamin D supplementation (vitamin D2: 50,000-100,000 units/week) to normalize serum vitamin D would allow successful rechallenge therapy with statins.

Materials And Methods: Follow-up evaluation on vitamin D supplementation was done on 134 patients at 6 months (median 5.3), 103 patients at 12 months (median 12.2), and 82 patients at 24 months (median 24).

Results: Median entry serum vitamin D (22 ng/mL, 23 ng/mL, and 23 ng/mL) rose at 6 months, 12 months, and 24 months follow-up to 53 ng/mL, 53 ng/mL, and 55 ng/mL, respectively, (P < .0001 for all) on vitamin D therapy (50,000-100,000 units/week). On vitamin D supplementation, serum vitamin D normalized at 6 months, 12 months, and 24 months follow-up in 90%, 86%, and 91% of the patients, respectively. On rechallenge with statins while on vitamin D supplementation, median low-density lipoprotein cholesterol (LDLC) fell from the study entry (167 mg/dL, 164 mg/dL, and 158 mg/dL) to 90 mg/dL, 91 mg/dL, and 84 mg/dL, respectively, (P < .0001 for all). On follow-up at median 6 months, 12 months, and 24 months on statins and vitamin D, 88%, 91%, and 95% of the previously statin-intolerant patients, respectively, were free of myalgia, myositis, myopathy, and/or myonecrosis.

Conclusions: Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis associated with low serum vitamin D can be safely resolved by vitamin D supplementation (50,000-100,000 units /week) in most cases (88-95%).

Citing Articles

A Case of Statin-Induced Necrotizing Autoimmune Myopathy.

Desai I, Modi S, Subhan A Cureus. 2024; 16(10):e70852.

PMID: 39493067 PMC: 11531928. DOI: 10.7759/cureus.70852.

Case Report: Severe vitamin D deficiency in a girl with inflammatory myopathy and myonecrosis.

Kanouse A, Nwosu B, Salemi P Front Pediatr. 2024; 12:1339875.

PMID: 38410767 PMC: 10894911. DOI: 10.3389/fped.2024.1339875.

Association Between Vitamin D Levels and COVID-19 Infection in Children: A Case-Control Study.

Bayrak H, Ozturk D, Bolat A, Unay B Turk Arch Pediatr. 2023; 58(3):250-255.

PMID: 37017281 PMC: 10210747. DOI: 10.5152/TurkArchPediatr.2023.22217.

Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy.

Beltran R, Zemeir K, Kimberling C, Kneer M, Mifflin M, Broderick T Int J Environ Res Public Health. 2022; 19(24).

PMID: 36554779 PMC: 9779535. DOI: 10.3390/ijerph192416899.

Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).

Penson P, Bruckert E, Marais D, Reiner Z, Pirro M, Sahebkar A J Cachexia Sarcopenia Muscle. 2022; 13(3):1596-1622.

PMID: 35969116 PMC: 9178378. DOI: 10.1002/jcsm.12960.

References

Morioka T, Lee A, Bertisch S, Buettner C . Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study. Atherosclerosis. 2014; 238(1):77-82. PMC: 4277894. DOI: 10.1016/j.atherosclerosis.2014.11.012. View

Vandenberg B, Robinson J . Management of the patient with statin intolerance. Curr Atheroscler Rep. 2010; 12(1):48-57. DOI: 10.1007/s11883-009-0077-8. View

Riphagen I, van der Veer E, Muskiet F, DeJongste M . Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin. 2012; 28(7):1247-52. DOI: 10.1185/03007995.2012.702102. View

Erkal M, Wilde J, Bilgin Y, Akinci A, Demir E, Bodeker R . High prevalence of vitamin D deficiency, secondary hyperparathyroidism and generalized bone pain in Turkish immigrants in Germany: identification of risk factors. Osteoporos Int. 2006; 17(8):1133-40. DOI: 10.1007/s00198-006-0069-2. View

Tirkkonen T, Heikkila P, Vahlberg T, Huupponen R, Laine K . Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences. Cardiovasc Ther. 2013; 31(6):344-51. DOI: 10.1111/1755-5922.12028. View

Lee P, Greenfield J, Campbell L . Vitamin D insufficiency--a novel mechanism of statin-induced myalgia?. Clin Endocrinol (Oxf). 2009; 71(1):154-5. DOI: 10.1111/j.1365-2265.2008.03448.x. View

Scott D, Blizzard L, Fell J, Jones G . Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM. 2009; 102(9):625-33. DOI: 10.1093/qjmed/hcp093. View

Tsugawa N, Suhara Y, Kamao M, Okano T . Determination of 25-hydroxyvitamin D in human plasma using high-performance liquid chromatography--tandem mass spectrometry. Anal Chem. 2005; 77(9):3001-7. DOI: 10.1021/ac048249c. View

Bischoff-Ferrari H, Dietrich T, Orav E, Hu F, Zhang Y, Karlson E . Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am J Clin Nutr. 2004; 80(3):752-8. DOI: 10.1093/ajcn/80.3.752. View

10.

Nichols G, Koro C . Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007; 29(8):1761-70. DOI: 10.1016/j.clinthera.2007.08.022. View

11.

Harari M, Dramsdahl E, Shany S, Baumfeld Y, Ingber A, Novack V . Increased vitamin D serum levels correlate with clinical improvement of rheumatic diseases after Dead Sea climatotherapy. Isr Med Assoc J. 2011; 13(4):212-5. View

12.

Simpson R, Thomas G, ARNOLD A . Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem. 1985; 260(15):8882-91. View

13.

Lips P . Vitamin D physiology. Prog Biophys Mol Biol. 2006; 92(1):4-8. DOI: 10.1016/j.pbiomolbio.2006.02.016. View

14.

Glerup H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Andersen H . Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int. 2000; 66(6):419-24. DOI: 10.1007/s002230010085. View

15.

Linde R, Peng L, Desai M, Feldman D . The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol. 2011; 2(2):77-84. PMC: 3081682. DOI: 10.4161/derm.2.2.13509. View

16.

Glueck C, Rawal B, Khan N, Yeramaneni S, Goldenberg N, Wang P . Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?. Metabolism. 2009; 58(2):233-8. DOI: 10.1016/j.metabol.2008.09.019. View

17.

Pfeifer M, Begerow B, Minne H . Vitamin D and muscle function. Osteoporos Int. 2002; 13(3):187-94. DOI: 10.1007/s001980200012. View

18.

Kurnik D, Hochman I, Vesterman-Landes J, Kenig T, Katzir I, Lomnicky Y . Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins. Clin Endocrinol (Oxf). 2012; 77(1):36-41. DOI: 10.1111/j.1365-2265.2011.04321.x. View

19.

Fang S, Wu J . Resolution of statin-induced myalgias by correcting vitamin D deficiency. South Med J. 2011; 104(5):380. DOI: 10.1097/SMJ.0b013e318213d123. View

20.

Ahmed W, Khan N, Glueck C, Pandey S, Wang P, Goldenberg N . Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res. 2008; 153(1):11-6. DOI: 10.1016/j.trsl.2008.11.002. View